ImmunoScape
Singapore, Singapore· Est.
A Singapore biotech delivering next‑generation TCR‑T cell therapies via a seed‑and‑boost platform for solid‑tumor oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
A Singapore biotech delivering next‑generation TCR‑T cell therapies via a seed‑and‑boost platform for solid‑tumor oncology.
Oncology
Technology Platform
Seed‑and‑boost immunotherapy that pairs low‑dose, naturally occurring TCR‑T cells with an off‑the‑shelf booster (CUE‑102) to selectively expand tumor‑specific T cells in vivo.
Opportunities
Scalable, cost‑effective cell‑therapy platform can unlock large solid‑tumor markets and attract strategic alliances with big pharma.
Risk Factors
Demonstrating clinical superiority and safety over existing CAR‑T/TCR‑T products; regulatory complexity of combination biologics.
Competitive Landscape
Competes with CAR‑T and TCR‑T developers; differentiation lies in low‑dose, off‑the‑shelf booster that reduces toxicity and manufacturing burden.